HIV Infection and Risk of Cardiovascular Diseases Beyond Coronary Artery Disease

Current Atherosclerosis Reports

Volumn 19, Issue 5, 2017, Pages

  Barnes, Revery P ^a   Lacson, John Charles A ^a   Bahrami, Hossein ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Atrial fibrillation; Cardiovascular disease; Heart failure; HIV infection; Stroke; Sudden cardiac death

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; BOSENTAN; DIGOXIN; DIURETIC AGENT; IMMUNOGLOBULIN; PROSTAGLANDIN; TELMISARTAN; ZIDOVUDINE;

ANTIRETROVIRAL THERAPY; ANTIVIRAL ACTIVITY; AORTA; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC INFLAMMATION; CORONARY ARTERY DISEASE; DRUG EFFECT; HEART FAILURE; HEART MUSCLE FIBROSIS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; PATHOGENESIS; PERICARDIAL EFFUSION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PULMONARY HYPERTENSION; REVIEW; SUDDEN CARDIAC DEATH; COMPLICATION; PATHOPHYSIOLOGY; RISK; VIROLOGY;

CARDIOVASCULAR DISEASES; HIV INFECTIONS; HUMANS; RISK;

EID: 85015863512     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-017-0652-3     Document Type: Review

References (91)

1. Lacson JC, Barnes RP, Bahrami H. Coronary artery disease in HIV infected patients: downside of living. Curr Atheroscler Rep. 2017:19(4). doi:10.1007/s11883-017-0651-4.
2. • Cerrato E et al. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. Eur Heart J. 2013;34(19):1432–6. The paper is a systematic review of recent studies on cardiac dysfunction in HIV-infected patients.
3. Barbaro G. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5(4):337–43.
4. Al-Kindi SG et al. Heart failure in patients with human immunodeficiency virus infection: epidemiology and management disparities. Int J Cardiol. 2016;218:43–6.
5. Bahrami H, Fonarow G, Heidenreich P. Heart failure admission in HIV-infected patients. J Am Coll Cardiol. 2014;63:(12_S).
6. Butt AA et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med. 2011;171(8):737–43.
7. Cannillo M et al. Heart failure in patients with human immunodeficiency virus: a review of the literature. J Cardiovasc Med (Hagerstown). 2015;16(5):383–9.
8. McIntosh RC. A meta-analysis of HIV and heart rate variability in the era of antiretroviral therapy. Clin Auton Res. 2016;26(4):287–94.
9. Lebech AM et al. Autonomic dysfunction in HIV patients on antiretroviral therapy: studies of heart rate variability. Clin Physiol Funct Imaging. 2007;27(6):363–7.
10. Bahrami H, et al. Inflammatory markers associated with subclinical coronary artery disease: the multicenter AIDS cohort study. J Am Heart Assoc. 2016;5:(6).
11. Neuhaus J et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201(12):1788–95.
12. Tenorio AR et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210(8):1248–59.
13. Bahrami H et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol. 2008;51(18):1775–83.
14. Nayak G et al. Cardiac diastolic dysfunction is prevalent in HIV-infected patients. AIDS Patient Care STDS. 2009;23(4):231–8.
15. • Hsue PY et al. Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail. 2010;3(1):132–9. This article showed the increased rates of diastolic dysfunction in PLWH.
16. Ntusi N et al. HIV-1-related cardiovascular disease is associated with chronic inflammation, frequent pericardial effusions, and probable myocardial edema. Circ Cardiovasc Imaging. 2016;9(3):e004430.
17. Blaylock JM et al. Longitudinal assessment of cardiac diastolic function in HIV-infected patients. Int J STD AIDS. 2012;23(2):105–10.
18. Luo L et al. Assessment of cardiac diastolic dysfunction in HIV-infected people without cardiovascular symptoms in China. Int J STD AIDS. 2010;21(12):814–8.
19. Reinsch N et al. Echocardiographic findings and abnormalities in HIV-infected patients: results from a large, prospective, multicenter HIV-heart study. Am J Cardiovasc Dis. 2011;1(2):176–84.
20. Lai H et al. HIV infection and abnormal regional ventricular function. Int J Cardiovasc Imaging. 2009;25(8):809–17.
21. •• Holloway CJ et al. Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients. Circulation. 2013;128(8):814–22. This is an important study that used advanced cardiac MRI to show higher rates of myocardial fibrosis and steatosis in HIV-infected patients, even on ART.
22. Thiara DK et al. Abnormal myocardial function is related to myocardial steatosis and diffuse myocardial fibrosis in HIV-infected adults. J Infect Dis. 2015;212(10):1544–51.
23. Bahrami H et al. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med. 2008;168(19):2138–45.
24. Taylor AL et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049–57.
25. CDC, Centers for Disease Control and Prevention. HIV Surveillance Report. 2015.
26. Bloomfield GS et al. Human immunodeficiency virus and heart failure in low- and middle-income countries. JACC Heart Fail. 2015;3(8):579–90.
27. Daniels LB et al. Serial measurement of N-terminal pro-B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2015;170(6):1170–83.
28. Choi EY et al. N-terminal pro-B-type natriuretic peptide, left ventricular mass, and incident heart failure: Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail. 2012;5(6):727–34.
29. Duprez DA et al. N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients. AIDS. 2011;25(5):651–7.
30. Secemsky EA et al. Novel biomarkers of cardiac stress, cardiovascular dysfunction, and outcomes in HIV-infected individuals. JACC Heart Fail. 2015;3(8):591–9.
31. Wong RW et al. Digoxin suppresses HIV-1 replication by altering viral RNA processing. PLoS Pathog. 2013;9(3):e1003241.
32. Lake JE et al. Telmisartan increases vascular reparative capacity in older HIV-infected adults: a pilot study. HIV Clin Trials. 2016;17(6):225–32.
33. Lipshultz SE et al. Immunoglobulins and left ventricular structure and function in pediatric HIV infection. Circulation. 1995;92(8):2220–5.
34. Uriel N et al. Advanced heart failure in patients infected with human immunodeficiency virus: is there equal access to care? J Heart Lung Transplant. 2014;33(9):924–30.
35. Aguero F et al. An update on heart transplantation in human immunodeficiency virus-infected patients. Am J Transplant. 2016;16(1):21–8.
36. Dries DL et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;32(3):695–703.
37. • Hsu JC et al. Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity. J Am Coll Cardiol. 2013;61(22):2288–95. The study showed higher risk of atrial fibrillation in PLWH.
38. Krahn AD et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med. 1995;98(5):476–84.
39. Chau KH et al. Abstract 13842: association of CHADS2VASc score and warfarin use with thromboembolic risk among HIV-infected persons with atrial fibrillation. Circulation. 2016;134 Suppl 1:A13842.
40. Grunfeld C et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS. 2009;23(14):1841–9.
41. Hsue PY et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109(13):1603–8.
42. Sims A et al. Abnormal cardiac strain in children and young adults with HIV acquired in early life. J Am Soc Echocardiogr. 2012;25(7):741–8.
43. Baker JV et al. Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. AIDS. 2014;28(6):831–40.
44. Esser S et al. Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study. Clin Res Cardiol. 2013;102(3):203–13.
45. Lo J et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010;24(2):243–53.
46. Hsue PY, Tawakol A. Inflammation and fibrosis in HIV: getting to the heart of the matter. Circ Cardiovasc Imaging. 2016;9(3):e004427.
47. Ng B et al. Heart failure in HIV infection: focus on the role of atherosclerosis. Curr Opin Cardiol. 2014;29(2):174–9.
48. Barnett CF, Hsue PY. Human immunodeficiency virus-associated pulmonary arterial hypertension. Clin Chest Med. 2013;34(2):283–92.
49. Ogunmola OJ, Oladosu YO, Olamoyegun MA. QTc interval prolongation in HIV-negative versus HIV-positive subjects with or without antiretroviral drugs. Ann Afr Med. 2015;14(4):169–76.
50. Tseng ZH et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol. 2012;59(21):1891–6.
51. Moyers BS et al. Effect of left ventricular dysfunction and viral load on risk of sudden cardiac death in patients with human immunodeficiency virus. Am J Cardiol. 2014;113(7):1260–5.
52. Benjamin LA et al. HIV infection and stroke: current perspectives and future directions. Lancet Neurol. 2012;11(10):878–90.
53. Yen YF, et al. Association of HIV and opportunistic infections with incident stroke: a nationwide population-based cohort study in Taiwan. J Acquir Immune Defic Syndr. 2016.
54. Rasmussen LD et al. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS. 2011;25(13):1637–46.
55. Chow FC et al. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr. 2012;60(4):351–8.
56. Sico JJ et al. HIV status and the risk of ischemic stroke among men. Neurology. 2015;84(19):1933–40.
57. Durand M et al. Risk of spontaneous intracranial hemorrhage in HIV-infected individuals: a population-based cohort study. J Stroke Cerebrovasc Dis. 2013;22(7):e34–41.
58. Thakur KT et al. Stroke in HIV-infected African Americans: a retrospective cohort study. J Neurovirol. 2016;22(1):50–5.
59. Kelso NE, Sheps DS, Cook RL. The association between alcohol use and cardiovascular disease among people living with HIV: a systematic review. Am J Drug Alcohol Abuse. 2015;41(6):479–88.
60. Ortiz G et al. Mechanisms of ischemic stroke in HIV-infected patients. Neurology. 2007;68(16):1257–61.
61. Tipping B et al. Stroke in patients with human immunodeficiency virus infection. J Neurol Neurosurg Psychiatry. 2007;78(12):1320–4.
62. Heikinheimo T et al. Stroke outcomes in Malawi, a country with high prevalence of HIV: a prospective follow-up study. PLoS One. 2012;7(3):e33765.
63. Chow FC et al. Elevated rates of intracerebral hemorrhage in individuals from a US clinical care HIV cohort. Neurology. 2014;83(19):1705–11.
64. Benjamin LA et al. Arterial ischemic stroke in HIV: defining and classifying etiology for research studies. Neurol Neuroimmunol Neuroinflamm. 2016;3(4):e254.
65. Mochan A, Modi M, Modi G. Stroke in black South African HIV-positive patients: a prospective analysis. Stroke. 2003;34(1):10–5.
66. • Benjamin LA et al. HIV infection and stroke: current perspectives and future directions. Lancet Neurol. 2012;11(10):878–90. The paper summarizes some of the most important studies on stroke in PLWH.
67. Benjamin LA et al. HIV, antiretroviral treatment, hypertension, and stroke in Malawian adults: a case-control study. Neurology. 2016;86(4):324–33.
68. Lachaud S, Suissa L, Mahagne MH. Stroke, HIV and meningovascular syphilis: study of three cases. Rev Neurol (Paris). 2010;166(1):76–82.
69. Hsue PY, et al. Carotid intima-media thickness progression in HIV-infected adults occurs preferentially at the carotid bifurcation and is predicted by inflammation. J Am Heart Assoc. 2012;1:(2).
70. Sainz T et al. Subclinical atherosclerosis and markers of immune activation in HIV-infected children and adolescents: the CaroVIH Study. J Acquir Immune Defic Syndr. 2014;65(1):42–9.
71. Hsue PY et al. Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium. Am J Cardiol. 2012;109(5):742–7.
72. Johnsen S et al. Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab. 2006;91(12):4916–24.
73. Hanna DB et al. HIV infection and carotid artery intima-media thickness: pooled analyses across 5 cohorts of the NHLBI HIV-CVD collaborative. Clin Infect Dis. 2016;63(2):249–56.
74. Vos AG et al. Pro-inflammatory markers in relation to cardiovascular disease in HIV infection. A systematic review. PLoS One. 2016;11(1):e0147484.
75. Knudsen A et al. HIV infection and arterial inflammation assessed by (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET): a prospective cross-sectional study. J Nucl Cardiol. 2015;22(2):372–80.
76. Subramanian S et al. Arterial inflammation in patients with HIV. JAMA. 2012;308(4):379–86.
77. Floris-Moore M et al. Association of HIV viral load with monocyte chemoattractant protein-1 and atherosclerosis burden measured by magnetic resonance imaging. AIDS. 2009;23(8):941–9.
78. Dua A, Lee CJ. Epidemiology of peripheral arterial disease and critical limb ischemia. Tech Vasc Interv Radiol. 2016;19(2):91–5.
79. Bernal E et al. Low prevalence of peripheral arterial disease in HIV-infected patients with multiple cardiovascular risk factors. J Acquir Immune Defic Syndr. 2008;47(1):126–7.
80. Periard D et al. High prevalence of peripheral arterial disease in HIV-infected persons. Clin Infect Dis. 2008;46(5):761–7.
81. Johns K et al. Ankle brachial index screening for occult vascular disease is not useful in HIV-positive patients. AIDS Res Hum Retroviruses. 2010;26(9):955–9.
82. Kwiatkowska W et al. Peripheral arterial disease and ankle-brachial index abnormalites in young and middle-aged HIV-positive patients in lower Silesia, Poland. PLoS One. 2014;9(12):e113857.
83. Knudsen A et al. Low prevalence of peripheral arterial disease in a cross-sectional study of Danish HIV-infected patients. Infect Dis (London). 2015;47(11):776–82.
84. Pham TV, Torres M. Human immunodeficiency virus infection-related heart disease. Emerg Med Clin North Am. 2015;33(3):613–22.
85. Lind A et al. Pericardial effusion of HIV-infected patients? Results of a prospective multicenter cohort study in the era of antiretroviral therapy. Eur J Med Res. 2011;16(11):480–3.
86. Hoeper MM et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4(4):306–22.
87. Correale M et al. HIV-associated pulmonary arterial hypertension: from bedside to the future. Eur J Clin Invest. 2015;45(5):515–28.
88. Sitbon O et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med. 2008;177(1):108–13.
89. Janda S, Quon BS, Swiston J. HIV and pulmonary arterial hypertension: a systematic review. HIV Med. 2010;11(10):620–34.
90. Pellicelli AM et al. Primary pulmonary hypertension in HIV patients: a systematic review. Angiology. 2001;52(1):31–41.
91. Henriques-Forsythe M, Annangi S, Farber HW. Prevalence and hospital discharge status of human immunodeficiency virus-associated pulmonary arterial hypertension in the United States. Pulm Circ. 2015;5(3):506–12.